Caroline Palomeque
Stock Analyst at Ladenburg Thalmann & Co.
(0.11)
# 4,384
Out of 4,456 analysts
174
Total ratings
31.3%
Success rate
-11.1%
Average return
Main Sectors:
Stocks Rated by Caroline Palomeque
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATHE Alterity Therapeutics | Initiated Coverage: Buy | $10 | $4.82 | +107.47% | 1 | Jun 16, 2026 | |
| ARDX Ardelyx | Initiated Coverage: Buy | $16 | $5.55 | +188.29% | 1 | Jun 16, 2026 | |
| KRYS Krystal Biotech | Initiated Coverage: Buy | $154 | $372.25 | n/a | 2 | Oct 25, 2023 | |
| HRMY Harmony Biosciences Holdings | Initiated Coverage: Buy | $59 → $54 | $35.47 | n/a | 2 | Oct 25, 2023 | |
| HALO Halozyme Therapeutics | Maintained: Buy | $58 | $74.96 | n/a | 7 | Sep 11, 2023 | |
| ASND Ascendis Pharma | Maintained: Buy | $166 | $260.75 | n/a | 12 | Sep 7, 2023 | |
| CMPS COMPASS Pathways | Maintained: Buy | $33 | $14.82 | n/a | 7 | Aug 16, 2023 | |
| ATAI AtaiBeckley | Reiterated: Buy | $11 | $5.29 | n/a | 6 | Aug 11, 2023 | |
| AVXL Anavex Life Sciences | Maintained: Buy | $40 | $2.62 | n/a | 24 | Aug 9, 2023 | |
| DNLI Denali Therapeutics | Reiterated: Buy | $54 | $25.57 | n/a | 14 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 | $9.84 | n/a | 7 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 | $10.48 | n/a | 12 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $10 | $18.20 | n/a | 2 | Apr 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $5 | $4.41 | n/a | 5 | Apr 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $2.09 | n/a | 8 | Apr 4, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 | $0.702 | n/a | 14 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.4948 | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $0.93 | n/a | 13 | Mar 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $4 → $40 | $1.65 | n/a | 11 | Mar 20, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | 1,364p | $633.00 | n/a | 2 | Mar 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $34 | $0.43 | n/a | 3 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $20 | $8.74 | n/a | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $9 | $2.11 | n/a | 6 | Mar 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $8 | $9.94 | n/a | 1 | Aug 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.000001 | n/a | 1 | Jun 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.0056 | n/a | 1 | Jun 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $2.55 | n/a | 1 | May 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $0.054 | n/a | 1 | Apr 24, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $18 | $0.0015 | n/a | 1 | Mar 2, 2016 |
Alterity Therapeutics
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $10
Current: $4.82
Upside: +107.47%
Ardelyx
Jun 16, 2026
Initiated Coverage: Buy
Price Target: $16
Current: $5.55
Upside: +188.29%
Krystal Biotech
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $154
Current: $372.25
Upside: n/a
Harmony Biosciences Holdings
Oct 25, 2023
Initiated Coverage: Buy
Price Target: $59 → $54
Current: $35.47
Upside: n/a
Halozyme Therapeutics
Sep 11, 2023
Maintained: Buy
Price Target: $58
Current: $74.96
Upside: n/a
Ascendis Pharma
Sep 7, 2023
Maintained: Buy
Price Target: $166
Current: $260.75
Upside: n/a
COMPASS Pathways
Aug 16, 2023
Maintained: Buy
Price Target: $33
Current: $14.82
Upside: n/a
AtaiBeckley
Aug 11, 2023
Reiterated: Buy
Price Target: $11
Current: $5.29
Upside: n/a
Anavex Life Sciences
Aug 9, 2023
Maintained: Buy
Price Target: $40
Current: $2.62
Upside: n/a
Denali Therapeutics
Aug 9, 2023
Reiterated: Buy
Price Target: $54
Current: $25.57
Upside: n/a
Aug 8, 2023
Maintained: Buy
Price Target: $15
Current: $9.84
Upside: n/a
Aug 3, 2023
Maintained: Buy
Price Target: $61
Current: $10.48
Upside: n/a
Apr 29, 2019
Maintained: Buy
Price Target: $10
Current: $18.20
Upside: n/a
Apr 23, 2019
Rated: Buy
Price Target: $5
Current: $4.41
Upside: n/a
Apr 4, 2019
Maintained: Buy
Price Target: $3
Current: $2.09
Upside: n/a
Apr 1, 2019
Maintained: Buy
Price Target: $6
Current: $0.702
Upside: n/a
Apr 1, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.4948
Upside: n/a
Mar 28, 2019
Maintained: Buy
Price Target: $9
Current: $0.93
Upside: n/a
Mar 20, 2019
Rated: Buy
Price Target: $4 → $40
Current: $1.65
Upside: n/a
Mar 14, 2019
Maintained: Buy
Price Target: 1,364p
Current: $633.00
Upside: n/a
Mar 20, 2018
Rated: Buy
Price Target: $34
Current: $0.43
Upside: n/a
Mar 13, 2018
Rated: Buy
Price Target: $20
Current: $8.74
Upside: n/a
Mar 9, 2018
Rated: Buy
Price Target: $9
Current: $2.11
Upside: n/a
Aug 8, 2017
Rated: Buy
Price Target: $8
Current: $9.94
Upside: n/a
Jun 13, 2017
Rated: Buy
Price Target: n/a
Current: $0.000001
Upside: n/a
Jun 7, 2017
Rated: Buy
Price Target: n/a
Current: $0.0056
Upside: n/a
May 17, 2017
Rated: Buy
Price Target: n/a
Current: $2.55
Upside: n/a
Apr 24, 2017
Rated: Buy
Price Target: n/a
Current: $0.054
Upside: n/a
Mar 2, 2016
Initiated Coverage: Buy
Price Target: $18
Current: $0.0015
Upside: n/a